Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae

Omadacycline, a novel aminomethylcycline with in vitro activity against Gram-positive and -negative organisms, including Streptococcus pneumoniae and Haemophilus influenzae, is approved in the United States to treat patients with community-acquired bacterial pneumonia (CABP). Using nonclinical pharm...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhavnani, Sujata M., Hammel, Jeffrey P., Lakota, Elizabeth A., Trang, Michael, Bader, Justin C., Bulik, Catharine C., VanScoy, Brian D., Rubino, Christopher M., Huband, Michael D., Friedrich, Lawrence, Steenbergen, Judith N., Ambrose, Paul G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112269/
https://www.ncbi.nlm.nih.gov/pubmed/36946741
http://dx.doi.org/10.1128/aac.02213-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112269/
https://www.ncbi.nlm.nih.gov/pubmed/36946741
http://dx.doi.org/10.1128/aac.02213-21

Ejemplares similares